In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens

International Journal of Antimicrobial Agents

Volumn 10, Issue 1, 1998, Pages 23-30

  Souli, Maria ^a,b   Wennersten, Christine B ^a   Eliopoulos, George M ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BAY 12 8039; Quinolone; Respiratory tract

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CEFUROXIME; CLAVULANIC ACID; ERYTHROMYCIN; FLUOROQUINOLONES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PENICILLIN RESISTANCE; QUINOLINES; QUINOLONES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0032052552     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00020-X     Document Type: Article

References (32)

1. Bartlett JG, Mundy LM Community-acquired pneumonia. New Engl J Med. 333:1995;1618-1624.
2. Eliopoulos GM In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs. 49(Suppl. 2):1995;48-57.
3. Eliopoulos GM, Eliopoulos CT Quinolone antimicrobial agents: Activity in vitro. Wolfson JS, Hooper DC Quinolone Antimicrobial Agents. 1989;35-70 American Society for Microbiology, Washington, DC.
4. Giamarellou H. Activity of quinolones against gram-positive cocci: Clinical features. Drugs. 49(2):1995;58-66.
5. Doern GV, Brueggemann A., Holley HP Jr, Rauch A. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30 center national surveillance study. Antimicrob Agents Chemother. 40:1996;1208-1213.
6. Hofmann J, Cetron M, Farley MM. et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. New Engl J Med. 333:1995;481-486.
7. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcellona, Spain. New Engl J Med. 333:1995;474-480.
8. Reichmann P, Varoni E, Gunther E et al. Penicillin-resistant Streptococcus pneumoniae in Germany: Genetic relationship to clones from other European countries. J Med Microbiol. 43:1995;377-385.
9. Holmström L., Nyman B, Rosengren M, Wallander S, Ripa T. Outbreaks of infections with erythromycin-resistant group A streptococci in child day care centers. Scand J Infect Dis. 22:1990;179-185.
10. Phillips G, Parratt D, Orange GV, Harper I, McEwan H, Young N. Erythromycin-resistant Streptococcus pyogenes. J Antimicrob Chemother. 25:1990;723-724.
11. Seppälä H, Nissinen A., Järvinen H. et al. Resistance to erthromycin in group A streptococci. New Engl J Med. 326:1992;292-297.
12. Doem GV, Brueggemann A., Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of, β lactamase-positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter surveillance study. Antimicrob Agents Chemother. 41:1997;292-297.
13. Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer. Clin Infect Dis. 20:1995;1169-1173.
14. Alcaide F, Carratala J, Linares J, Gudiol F, Martin R. In vitro activities of eight macrolide antibiotics and RP-5950 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients. Antimicrob Agents Chemother. 40:1996;2117-2120.
15. Doern GV, Ferraro MJ, Brueggemann A, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 40:1996;891-894.
16. Petersen U, Bremm KD, Dalhoff A, et al. Synthesis and in vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Abstract F1, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.
17. Souli M, Wennersten CB, Eliopoulos GM. In vitro activity of BAY 12-8039, a novel 8 methoxyquinolone, against species representative of respiratory tract pathogens. Abstract F126, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997.
18. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd edn. Approved Standard, NCCLS Doc. M7-A3, Villanova, PA, 1993.
19. Pankuch GA, Jacobs MP, Appelbaum PC. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 35:1995;883-888.
20. Eliopoulos GM, Reiszner E., Ferraro MJ, Wennersten C, Moellering RC. Jr Effect of growth medium on activity of fluoroquinolones and other antimicrobial agents against Legionella species. Rev Infect Dis. 10(Suppl.1):1988;56.
21. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 24(Suppl.1):1997;S67-S73.
22. Neu HC. Quinolone antimicrobial agents. Annu Rev Med. 43:1992;465-486.
23. Prosser BLT, Beskid G. Multicenter in vitro comparative study of fluoroquinolones against 25, 129 gram-positive and gram-negative clinical isolates. Diagn Microbiol Infect Dis. 21:1995;33-45.
24. Kubitza D, Stass HH, Wingender W, Kuhimann J. BAY 12-8039, a new 8 methoxyquinolone: safety, tolerability and steady-state pharmacokinetics in healthy male volunteers. Abstract F25, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.
25. Stass HH, Dalhoff A, Kubitza D, Ahr G. BAY 12-8039, a new 8- methoxyquinolone: first pharmacokinetic results in healthy male volunteers. Abstract F24, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.
26. Vohr HW, Wasinska-Kempka G, Ahr HJ. Studies on the phototoxic potential of BAY 12-8039. Abstract F21, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.
27. Georgopoulos A, Buxbaum A, Graninger W. Activity of BAY 12-8039 against 1154 clinical isolates of Streptococcus pneumoniae. Abstract F5, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996.
28. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 41:1997;101-106.
29. Fass RJ. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother. 41:1997;1818-1824.
30. Reinert RR, Dalhoff A., Schlaeger JJ, Lemperle M, Lutticken R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone, against Streptococcus pneumoniae. Abstract F129, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997.
31. Brueggemann AB, Kugler KC, Doem GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 41:1997;1594-1597.
32. Neu HC. Bacterial resistance to fluoroquinolones. Rev Infect Dis. 10(Suppl.1):1988;S57-S63.